The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2646-2654

  Louie, Arnold ^a   Grasso, Caroline ^a   Bahniuk, Nadzeya ^a   Van Scoy, Brian ^a   Brown, David L ^a   Kulawy, Robert ^a   Drusano, G L ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; MEROPENEM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENTIATION; GENE OVEREXPRESSION; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; TANDEM MASS SPECTROMETRY;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENES, BACTERIAL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 77952607034     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00065-10     Document Type: Article

References (18)

1. Bilello, J. A., G. Bauer, M. N. Dudley, G. A. Cole, and G. L. Drusano. 1994. Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob. Agents Chemother. 38:1386-1391.
2. Blaser, J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130.
3. Blaser, J., B. J. Stone, and S. H. Zinner. 1985. Two compartment kinetic model with multiple artificial capillary units. J. Antimicrob. Chemother. 15(Suppl. A):131-137.
4. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. CLSI publication M7-A7. CLSI, Wayne, PA.
5. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II. A program for simulation, identification, and optimal experimental design. User manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA. http://bmsr.usc.edu/.
6. Drusano, G. L., C. Fregeau, W. Liu, D. L. Brown, and A. Louie. 2008. Impact of granulocytes on clearance of infection in a mouse thigh infection model: Pseudomonas aeruginosa is different from Staphylococcus aureus, abstr. A-992. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
7. Drusano, G. L., W. Liu, C. Fregeau, R. Kulawy, and A. Louie. 2009. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance on wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob. Agents Chemother. 53:2266-2273.
8. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., R. H. Johnson, S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, and G. A. Siami. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob. Agents Chemother. 38:547-557.
9. Gumbo, T., A. Louie, M. R. Deziel, L. M. Parsons, M. Salfinger, and G. L. Drusano. 2004. Selection of a moxifloxacin dose that suppresses Mycobacterium tuberculosis resistance using an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 190:1642-1651.
10. Jumbe, N., A. Louie, R. Leary, W. Liu, M. R. Deziel, V. H. Tam, R. Bachhawat, C. Freeman, J. B. Kahn, K. Bush, M. N. Dudley, M. H. Miller, and G. L. Drusano. 2003. Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285.
11. Murakami, S., R. Nakashima, E. Yamashita, T. Matsumoto, and A. Yamaguchi. 2006. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443:173-179. (Pubitemid 44387601)
12. Peloquin, C. A., T. J. Cumbo, D. E. Nix, M. F. Sands, and J. J. Schentag. 1989. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentration and clinical condition on bacterial eradication. Arch. Intern. Med. 149:2269-2273.
13. Schimpff, S., W. Satterlee, V. M. Young, and A. Serpick. 1971. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N. Engl. J. Med. 284:1061-1065.
14. Selkon, J. B., S. Devadatta, K. G. Kulkarni, D. A. Mitchison, A. S. Narayana, C. N. Nair, and K. Ramachandran. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull. World Health Organ. 31:273-294.
15. Tam, V. H., A. Louie, M. R. Deziel, W. Liu, and G. L. Drusano. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob. Agents Chemother. 51: 744-747.
16. Tam, V. H., A. Louie, T. R. Fritsche, M. Deziel, W. Liu, D. L. Brown, L. Deshpande, R. Leary, R. N. Jones, and G. L. Drusano. 2007. Drug exposure intensity and duration of therapy's impact on emergence of resistance of Staphylococcus aureus to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827.
17. Uchino, S., J. A. Kellum, R. Bellomo, G. S. Doig, H. Morimatsu, S. Morgera, M. Schetz, I. Tan, C. Bouman, E. Macedo, N. Gibney, A. Tolwany, and C. Ronco. 2005. Acute renal failure in critically ill patients: a multinational, multicenter study. Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. JAMA 294:813-818.
18. West, M., B. R. Boulanger, C. Fogarty, A. Tennenberg, B. Weisinger, M. Oross, S.-C. Wu, and J. B. Kahn. 2003. Levofloxacin versus imipenem/cilastatin followed by ciprofloxacin in the treatment of nosocomial pneumonia: a prospective, randomized, multicenter study. Clin. Ther. 25:486-506.